MedTrace Logo

Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

NCT01460979 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2016-02-29

No results posted yet for this study

Summary

The purpose of this study is to determine the activity, tolerability and safety of Temsirolimus in women with ovarian cancer who progressed during the previous platinum chemotherapy alternatively within 6 months from completion of therapy or advanced endometrial carcinoma.

Conditions

  • Genital Diseases, Female
  • Ovarian Diseases
  • Ovarian Neoplasms
  • Endometrial Neoplasms

Interventions

DRUG

Temsirolimus

25mg weekly intravenous until progression

Sponsors & Collaborators

  • AGO Study Group

    lead OTHER

Principal Investigators

  • Günter Emons, Professor · AGO Study Group (Study Group of the Arbeitsgemeinschaft Gynaekologische Onkologie)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2015-06-30
Completion
2015-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01460979 on ClinicalTrials.gov